Association Between the Endocannabinoid System-Related Gene Variants and Epilepsy.
CNR1
CNR2
DAGLA
Endocannabinoid system
Epilepsy
MGLL
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
05 Apr 2024
05 Apr 2024
Historique:
received:
26
10
2023
accepted:
18
03
2024
medline:
5
4
2024
pubmed:
5
4
2024
entrez:
5
4
2024
Statut:
aheadofprint
Résumé
The endocannabinoid system (ECS) is an intricate network consisting of receptors, enzymes, and endogenous ligands that play a pivotal role in various neurological processes. It has been implicated in the pathophysiology of several neurological disorders, including epilepsy. Extensive research has demonstrated the involvement of genetic factors in influencing the susceptibility to and progression of epilepsy. In this study, we focused on investigating the connection between genetic variations in genes related to the ECS and the occurrence of epilepsy. Some ECS-related gene variants were selected and genotyping was performed using the polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) technique. Interestingly, CNR1 rs12720071 genotype (OR 16.33, 95% CI 1.8-149; p = 0.001) showed an association with generalized epilepsy and MGLL rs604300 genotype (OR 2, 95% CI 1.1-3.4; p = 0.013) demonstrated a relationship with females diagnosed with focal epilepsy. So, studying CNR1, MGLL, and their genetic variations provides insights into the role of the endocannabinoid system in health and diseases. Moreover, they hold the potential to pave the way for the development of novel therapeutic approaches specifically targeting them.
Identifiants
pubmed: 38578355
doi: 10.1007/s12035-024-04132-5
pii: 10.1007/s12035-024-04132-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lu HC, Mackie K (2021) Review of the endocannabinoid system. Biol Psychiatry Cogn Neurosci Neuroimaging 6:607–615
pubmed: 32980261
Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017–1066
doi: 10.1152/physrev.00004.2003
pubmed: 12843414
Atwood BK, Mackie K (2010) CNR2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467–479
doi: 10.1111/j.1476-5381.2010.00729.x
pubmed: 20590558
pmcid: 2931549
Busquets-Garcia A, Bains J, Marsicano G (2018) CB(1) Receptor signaling in the brain: extracting specificity from ubiquity. Neuropsychopharmacology 43:4–20
doi: 10.1038/npp.2017.206
pubmed: 28862250
Demuth DG, Molleman A (2006) Cannabinoid signalling. Life Sci 78:549–563
doi: 10.1016/j.lfs.2005.05.055
pubmed: 16109430
J. E. W. H. O. h. w. w. i. n.-r. f.-s. d. e. World Health Organization.
Pertwee RG (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 367:3353–3363
doi: 10.1098/rstb.2011.0381
pubmed: 23108552
pmcid: 3481523
Cao Q, Yang F, Wang H (2021) CNR2R induces a protective response against epileptic seizures through ERK and p38 signaling pathways. Int J Neurosci 131:735–744
doi: 10.1080/00207454.2020.1796661
pubmed: 32715907
Blair RE, Deshpande LS, Sombati S, Falenski KW, Martin BR, DeLorenzo RJ (2006) Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J Pharmacol Exp Ther 317:1072–1078
doi: 10.1124/jpet.105.100354
pubmed: 16469864
Amini M, Saboory E, Derafshpour L, Fakhari A, Wu JC, Bruggeman R, Asgharzadeh F, Ahmadalipour A (2020) The impact of sleep deprivation on sexual behaviors and FAAH expression in the prefrontal cortex of male rats. Neurosci Lett 735:135254
doi: 10.1016/j.neulet.2020.135254
pubmed: 32682844
Mobed A, Kohansal F, Ahmadalipour A, Hasanzadeh M, Zargari F (2022) Correction: bioconjugation of 2-arachidonoyl glycerol (2-AG) biotinylated antibody with gold nano-flowers toward immunosensing of 2-AG in human plasma samples: a novel immuno-platform for the screening of immunomodulation and neuroprotection using biosensing. Anal Methods 14:4029
doi: 10.1039/D2AY90125K
pubmed: 36200431
von Ruden EL, Bogdanovic RM, Wotjak CT, Potschka H (2015) Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice. Neurobiol Dis 77:238–245
doi: 10.1016/j.nbd.2015.03.016
Sugaya Y, Yamazaki M, Uchigashima M, Kobayashi K, Watanabe M, Sakimura K, Kano M (2016) Crucial roles of the endocannabinoid 2-arachidonoylglycerol in the suppression of epileptic seizures. Cell Rep 16:1405–1415
doi: 10.1016/j.celrep.2016.06.083
pubmed: 27452464
Monteleone P, Bifulco M, Maina G, Tortorella A, Gazzerro P, Proto MC, Di Filippo C, Monteleone F, Canestrelli B, Buonerba G, Bogetto F, Maj M (2010) Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 61:400–404
doi: 10.1016/j.phrs.2010.01.002
pubmed: 20080186
Si P, Liu S, Tong D, Cheng M, Wang L, Cheng X (2018) Association of polymorphisms of NAPE-PLD and FAAH genes with schizophrenia in Chinese Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 35:215–218
pubmed: 29652995
Ahmadalipour A, Mehdizadeh Fanid L, Zeinalzadeh N, Alizadeh M, Vaezi H, Hassanpour Aydinlou Z, Noorazar SG (2020) The first evidence of an association between a polymorphism in the endocannabinoid-degrading enzyme FAAH (FAAH rs2295633) with attention deficit hyperactivity disorder. Genomics 112:1330–1334
doi: 10.1016/j.ygeno.2019.07.024
pubmed: 31377429
Anvar LH, Alejafar A, Moosavi SE, Charsouei S, Zeynalzadeh N, Fanid LM, Emamalizadeh B, Aydinlou ZH, Vaezi H, Kashefi A, Tomaz C, Nikanfar M, Ahmadalipour A (2023) The study of rs324420 (C385A) polymorphism of the FAAH gene of the endocannabinoid system in patients with epilepsy and ADHD. Epilepsy Res 192:107100
doi: 10.1016/j.eplepsyres.2023.107100
pubmed: 37018974
Hosseinzadeh Anvar L, Ahmadalipour A (2023) Fatty acid amide hydrolase C385A polymorphism affects susceptibility to various diseases. BioFactors 49:62–78
doi: 10.1002/biof.1911
pubmed: 36300805
Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, Morikawa M, Inada T, Watanabe Y, Takahashi M, Someya T, Ujike H, Iwata N, Ozaki N, Onaivi ES, Kunugi H, Sasaki T, Itokawa M, Arai M, Niizato K, Iritani S, Naka I, Ohashi J, Kakita A, Takahashi H, Nawa H, Arinami T (2010) Brain cannabinoid CNR2 receptor in schizophrenia. Biol Psychiatry 67:974–982
doi: 10.1016/j.biopsych.2009.09.024
pubmed: 19931854
Carey CE, Agrawal A, Zhang B, Conley ED, Degenhardt L, Heath AC, Li D, Lynskey MT, Martin NG, Montgomery GW, Wang T, Bierut LJ, Hariri AR, Nelson EC, Bogdan R (2015) Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: evidence from an endocannabinoid system-level analysis. J Abnorm Psychol 124:860–877
doi: 10.1037/abn0000079
pubmed: 26595473
pmcid: 4700831
Ferretjans R, de Souza RP, Panizzutti B, Ferrari P, Mantovani L, de Campos-Carli SM, Santos RR, Guimaraes FC, Teixeira AL, Gama CS, Salgado JV (2022) Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. Braz J Psychiatry 44:26–34
doi: 10.1590/1516-4446-2020-1650
pubmed: 34190825
Tong D, He S, Wang L, Jin L, Si P, Cheng X (2013) Association of single-nucleotide polymorphisms in the cannabinoid receptor 2 gene with schizophrenia in the Han Chinese population. J Mol Neurosci 51:454–460
doi: 10.1007/s12031-013-0062-0
pubmed: 23846977
Ishiguro H, Higuchi S, Arinami T, Onaivi ES (2018) Association between alcoholism and the gene encoding the endocannabinoid synthesizing enzyme diacylglycerol lipase alpha in the Japanese population. Alcohol 68:59–62
doi: 10.1016/j.alcohol.2017.09.005
pubmed: 29477030
Peiro AM, Garcia-Gutierrez MS, Planelles B, Femenia T, Mingote C, Jimenez-Trevino L, Martinez-Barrondo S, Garcia-Portilla MP, Saiz PA, Bobes J, Manzanares J (2020) Association of cannabinoid receptor genes (CNR1 and CNR2) polymorphisms and panic disorder. Anxiety Stress Coping 33:256–265
doi: 10.1080/10615806.2020.1732358
pubmed: 32114795
Navarrete F, Garcia-Gutierrez MS, Gasparyan A, Navarro D, Lopez-Picon F, Morcuende A, Femenia T, Manzanares J (2022) Biomarkers of the endocannabinoid system in substance use disorders. Biomolecules 12
h. f. g. c.-F. b. Genoox.
Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, Massouras A (2019) VarSome: the human genomic variant search engine. Bioinformatics 35:1978–1980
doi: 10.1093/bioinformatics/bty897
pubmed: 30376034
Wang J, Lin ZJ, Liu L, Xu HQ, Shi YW, Yi YH, He N, Liao WP (2017) Epilepsy-associated genes. Seizure 44:11–20
doi: 10.1016/j.seizure.2016.11.030
pubmed: 28007376
Prasad DK, Satyanarayana U, Munshi A (2013) Genetics of idiopathic generalized epilepsy: an overview. Neurol India 61:572–577
doi: 10.4103/0028-3886.125240
pubmed: 24441321
Rubino T, Parolaro D (2011) Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci 5:64
doi: 10.3389/fnbeh.2011.00064
pubmed: 21991251
pmcid: 3181427
Guennoun R (2020) Progesterone in the brain: hormone, neurosteroid and neuroprotectant. Int J Mol Sci 21:5271
doi: 10.3390/ijms21155271
pubmed: 32722286
pmcid: 7432434
Jameson JL, De Groot LJ, de Kretser DM, Giudice LC, Grossman AB, Melmed S, Potts Jr. JT and Weir GC (Eds.) (2016) Endocrinology: adult & pediatric. (7th ed.) Elsevier
Reddy DS, Thompson W, Calderara G (2021) Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis. Neurosci Lett 750:135753
doi: 10.1016/j.neulet.2021.135753
pubmed: 33610673
Dalic L, Cook MJ (2016) Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat 12:2605–2616
doi: 10.2147/NDT.S84852
pubmed: 27789949
pmcid: 5068473
Makowska M, Smolarz B, Brys M, Forma E, Romanowicz H (2021) An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children. Int J Neurosci 131:1147–1154
doi: 10.1080/00207454.2020.1781110
pubmed: 32567426
Seven M, Batar B, Unal S, Yesil G, Yuksel A, Guven M (2014) The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children. Mol Diagn Ther 18:229–236
doi: 10.1007/s40291-013-0078-8
pubmed: 24338437